지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한병리학회 Journal of Pathology and Translational Medicine Journal of Pathology and Translational Medicine 제45권 제1호
- 발행연도
- 2011.1
- 수록면
- 45 - 52 (8page)
이용수
초록· 키워드
오류제보하기
Background: The role of excision repair cross-complementation group 1 (ERCC1) has been controversial in non-small cell lung cancer (NSCLC) patients who received adjuvant chemotherapy with a platinum agent. We investigated ERCC1 expression in stage I-II NSCLC to clarify its significance for adjuvant chemotherapy. Methods: The ERCC1 expression profile was evaluated by immunohistochemistry and compared according to adjuvant chemotherapeutic agents in 146 patients who underwent surgical resection for stage I-II NSCLC. The patients were divided into 3 groups; adjuvant chemotherapy with a platinum based agent (18.5%, 27/146); adjuvant chemotherapy with uracil-tegafur (UFT) (40.4%, 59/146); surgery-alone (41.1%, 60/146). Results: Nuclear ERCC1 expression was detected in 71.9% (105/146) of NSCLC and was significantly associated with a shortened survival period in the group 1 patients who received the platinum based regimen after surgery. The group 2 patients who received UFT showed the longest survival period, followed by the surgery-alone group (overall survival, p=0.049; disease-free survival [DFS], p<0.001). Conclusions: These results suggest that stage I-II NSCLC patients with ERCC1 expression experience a shorter DFS period with adjuvant chemotherapy with a platinum based regimen and may benefit from adjuvant chemotherapy with UFT, instead of platinum after surgery.
목차
등록된 정보가 없습니다.
참고문헌 (20)
참고문헌 신청
Arriagada R / 2004 / Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer / N Engl J Med 350 : 351 ~ 360
Booton R / 2007 / ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer / J Th
Douillard JY / 2006 / Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine
Duffy MJ / 2011 / Use of molecular markers for predicting therapy response in cancer patients / Cancer Treat Rev 37 : 151 ~ 159
Fu JB / 2005 / Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database / Chest 127 : 768 ~ 777
Booton R / 2007 / ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer / J Th
Douillard JY / 2006 / Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine
Duffy MJ / 2011 / Use of molecular markers for predicting therapy response in cancer patients / Cancer Treat Rev 37 : 151 ~ 159
Fu JB / 2005 / Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database / Chest 127 : 768 ~ 777
이 논문의 저자 정보
최근 본 자료
댓글(0)
0